Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Author:

Yilmaz Emrullah1ORCID,Ismaila Nofisat2ORCID,Bauman Julie E.3ORCID,Dabney Raetasha4,Gan Gregory5,Jordan Richard6,Kaufman Marnie7ORCID,Kirtane Kedar8ORCID,McBride Sean Matthew9ORCID,Old Matthew O.10,Rooper Lisa11,Saba Nabil F.12ORCID,Sheth Siddharth13ORCID,Subramaniam Rathan M.1415ORCID,Wise-Draper Trisha Michel16ORCID,Wong Deborah17ORCID,Mell Loren K.18ORCID

Affiliation:

1. Cleveland Clinic, Cleveland, OH

2. American Society of Clinical Oncology, Alexandria, VA

3. George Washington University, Washington, DC

4. The Center for Cancer and Blood Disorder, Southlake, TX

5. Kansas University Medical Center, Kansas City, KS

6. University of California San Francisco, San Francisco, CA

7. Patient Representative, Needham Heights, MA

8. Moffitt Cancer Center, Tampa, FL

9. Memorial Sloan Kettering Cancer Center, New York, NY

10. Ohio State University, Columbus, OH

11. Johns Hopkins Medicine, Baltimore, MD

12. Emory University, Atlanta, GA

13. University of North Carolina, Chapel Hill, Chapel Hill, NC

14. Otago Medical School, University of Otago, Dunedin, New Zealand

15. Duke University, Durham, NC

16. University of Cincinnati, Cincinnati, OH

17. University of California Los Angeles, Los Angeles, CA

18. University of California San Diego, La Jolla, CA

Abstract

PURPOSE To provide evidence-based recommendations for practicing physicians and other health care providers on immunotherapy and biomarker testing for head and neck cancers. METHODS ASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, radiology, pathology, and patient advocacy experts to conduct a literature search, including systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2022. Outcomes of interest included survival, overall response, and locoregional control. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 28 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS When possible, evidence-based recommendations were developed to address biomarker testing, first-line treatment regimens based on programmed death ligand-1 scores, immunotherapy in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma, immunotherapy in nasopharyngeal carcinoma, and radiation therapy in combination with immunotherapy for treatment of local recurrence. Additional information is available at www.asco.org/head-neck-cancer-guidelines .

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3